ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2558

Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab

Fernando López1, Javier Loricera2, Adrián Martín-Gutiérrez3, Carmen Secada3, Santos Castañeda4, Clara Moriano Morales5, Javier Narvaez6, Vicente Aldasoro7, Olga Maiz8, Rafael Benito Melero-Gonzalez9, PALOMA VELA10, Susana Romero Yuste11, Eugenio De Miguel12, Eva Galindez-Agirregoikoa13, Jesús Carlos Fernández López14, Ivan Ferraz Amaro15, Julio Sánchez-Martín3, Jose L. Callejas16, Patricia Moya Albarado17 and Ricardo Blanco18, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5Rheumatology, Hospital Universitario de León, León, Spain, 6Hospital Universitario de Bellvitge, Barcelona, Spain, 7Hospital Universitario de Navarra, Pamplona, Spain, 8Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, 9CHU Vigo, O Carballino, Spain, 10Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 11Complexo Hospitalario Universitario, Pontevedra, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Basurto University Hospital, Bilbao, Spain, 14Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 15Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 16Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, 17Hospital Universitario de Sant Pau, Barcelona, Spain, 18Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, prevention, surgery

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless, to date, the usefulness of TCZ in aortic aneurysms has not been evaluated.
Our aim was to assess the role of TCZ in a) prevention of development of aneurysms, and b) impairment of aneurysm if present.

Methods: Observational, multicenter study of 196 patients with aortitis related to GCA treated with TCZ. Patients were diagnosed with GCA accordingly to a) American College of Rheumatology criteria, and/or b) positive biopsy of temporal artery, and/or c) the presence of imaging techniques consistent with LVV.

Patients with GCA-aortitis were divided into two subgroups: a) with, and b) without aortic aneurysms.

Results: We studied 196 (148 women/48 men; mean age 71.3±9.5 years) patients with aortitis related to GCA treated with TCZ. Aortitis was confirmed by PET in all cases. Aortic aneurysms were present in 10 of 196 (5%) patients when TCZ was initiated.

Imaging in follow-up was present in these 10 patients and in 95 of the remaining 186 patients, that were finally studied. Main general features of both groups are shown in TABLE 1. No significant differences were observed between the two groups except for the median serum CRP value, which was higher in the group of patients with aneurysms. After a mean follow-up of 25±19 months, none of the 95 GCA-aortitis patients without aneurysm at TCZ initiation developed any aneurysm.

In TABLE 2 are summarized the characteristics and follow-up of the 10 patients with aneurysms. Aneurysms were more frequently located in thoracic segment (n=5; 50%). Early surgery was required in 5 cases at TCZ initiation, and the usefulness of TCZ in these cases could not be assessed. From the remaining 5 patients, 3 patients experienced aneurysm growth despite TCZ therapy and a surgery was required during follow-up. The other 2 patients remained stable and did not require surgery due to the small size of the aneurysm.

Conclusion: Aortic aneurysms is a rare, but not exceptional complication in patients with aortitis related to GCA. In these patients, although TCZ could prevent the development of new aneurysms, it does not appear to prevent aneurysm growth.

References.

  1. Nuenninghoff DM, et al. Arthritis Rheum. 2003. PMID: 14674004
  2. Loricera J, et al. Rev Esp Med Nucl Imagen Mol. 2015. PMID: 26272121

Supporting image 1

Main features of 196 patients with aortitis related to GCA

Supporting image 2

Characteristics and outcome of aortic aneurysms in treatment with TCZ


Disclosures: F. López: None; J. Loricera: None; A. Martín-Gutiérrez: None; C. Secada: None; S. Castañeda: None; C. Moriano Morales: None; J. Narvaez: None; V. Aldasoro: None; O. Maiz: None; R. Melero-Gonzalez: None; P. VELA: AbbVie/Abbott, 5, AstraZeneca, 5, Eli Lilly, 5, 6, GlaxoSmithKlein(GSK), 6, Novartis, 5, Pfizer, 5; S. Romero Yuste: AbbVie, 6, AstraZeneca, 6, Biogen, 6, Lilly, 5, 6, Pfizer, 6, Sanofi, 1; E. De Miguel: None; E. Galindez-Agirregoikoa: None; J. Fernández López: None; I. Ferraz Amaro: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Bristol-Myers Squibb(BMS), 6; J. Sánchez-Martín: None; J. Callejas: None; P. Moya Albarado: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

López F, Loricera J, Martín-Gutiérrez A, Secada C, Castañeda S, Moriano Morales C, Narvaez J, Aldasoro V, Maiz O, Melero-Gonzalez R, VELA P, Romero Yuste S, De Miguel E, Galindez-Agirregoikoa E, Fernández López J, Ferraz Amaro I, Sánchez-Martín J, Callejas J, Moya Albarado P, Blanco R. Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/aortic-aneurysms-in-a-multicenter-cohort-of-196-patients-with-aortitis-related-to-giant-cell-arteritis-treated-with-tocilizumab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aortic-aneurysms-in-a-multicenter-cohort-of-196-patients-with-aortitis-related-to-giant-cell-arteritis-treated-with-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology